Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT)
conjugated to a linear, cyclodextrin-based polymer. CRLX101 is designed to increase the
exposure of tumor cells to CPT while minimizing side effects.
OBJECTIVES:
• Determine the safety, toxicity, and the maximum tolerated dose (MTD) of CRLX101 when
administered intravenously to subjects with advanced solid tumors.